Skip to main content
Log in

Influence of the Glomerular Filtration Rate on Renal Clearance of Ceftazidime in Cystic Fibrosis

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The renal handling of ceftazidime was studied in 8 patients with cystic fibrosis and 10 healthy controls. The renal clearance of ceftazidime (CLRcz) was measured after an intravenous single dose and during low and high plasma concentration steady-state infusions. The glomerular filtration rate (GFR) was simultaneously estimated by inulin clearance (CLinul). The average CLRcz (mean ± SD) was higher in cystic fibrosis patients (125 ± 20 ml/min/1.73m2) than in healthy controls (100 ± 9 ml/min/1.73m2) [p < 0.005]. Also CLinul (mean ± SD) was increased in cystic fibrosis patients (132 ± 30 ml/min/1.73m2) compared with healthy controls (103 ± 8 ml/min/1.73m2) [p < 0.02]. The mean renal clearance ratios of ceftazidime to inulin were close to unity after both the single dose and low and high dose steady-state infusions both in cystic fibrosis patients and in controls.

These findings suggest that the glomerular filtration rate is the principal determinant of the elimination rate of ceftazidime. However, in all cystic fibrosis patients with a CLinul exceeding 125 ml/min/1.73m2 the clearance ratio was below unity, indicating tubular reabsorption of ceftazidime occurs in these individuals. The results demonstrate a higher but also more variable GFR in cystic fibrosis patients (74 to 174 ml/min/1.73m2), resulting in increased and accordingly variable ability to eliminate ceftazidime in cystic fibrosis. However, these pharmacokinetic changes are not large enough to call for special dosage considerations for ceftazidime in cystic fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Arvidsson A, Alván G, Strandvik B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatrica Scandinavica 72: 293–294, 1983

    Article  PubMed  CAS  Google Scholar 

  • Arvidsson A, Borgå O, Alván G. Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption. Clinical Pharmacology and Therapeutics 25: 870–876, 1979

    PubMed  CAS  Google Scholar 

  • Aurell M, Granerus G. Njurfunktionsprov i vardagssjukvården. Läkartidningen 83: 604–607, 1986

    PubMed  CAS  Google Scholar 

  • Ayrton J. Assay of ceftazidime in biological fluids using high-pressure liquid chromatography. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 227–231, 1981

    PubMed  CAS  Google Scholar 

  • Berg U, Kusoffsky E, Strandvik B. Renal function in cystic fibrosis with special reference to the renal sodium handling. Acta Paediatrica Scandinavica 71: 833–838, 1982

    Article  PubMed  CAS  Google Scholar 

  • De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clinical Pharmacokinetics 13: 228–253, 1987

    Article  PubMed  Google Scholar 

  • Finkelstein E, Hall K. Aminoglycoside clearance in patients with cystic fibrosis. Journal of Pediatrics 94: 163–164, 1979

    PubMed  CAS  Google Scholar 

  • Granerus G, Aurell M. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scandinavian Journal of Clinical and Laboratory Investigation 41: 611–616, 1981

    Article  PubMed  CAS  Google Scholar 

  • Harding SM, Ayrton J, Thornton JE, Munro AJ, Hogg MIJ. Pharmacokinetics of ceftazidime in normal subjects. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 261, 1981a

    PubMed  Google Scholar 

  • Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MIJ. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 263–272, 1981b

    PubMed  CAS  Google Scholar 

  • Hilger HH, Klumper JD, Ullrich KJ. Wasserrückresorption und Jonentransport durch die Sammelsrohrzellen der Säugetierniere. Pflugers Archiv: European Journal of Physiology 267: 218–237, 1958

    Article  PubMed  CAS  Google Scholar 

  • Hoffstedt B, Haidle S, Walder M. Influence of probenecid on serum and subcutaneous tissue fluid concentrations of benzylpenicillin and ceftazidime in human volunteers. European Journal of Clinical Microbiology 2: 604–606, 1983

    Article  PubMed  CAS  Google Scholar 

  • Hultqvist C, Borgå O. Enprofylline pharmacokinetics in children with asthma. European Journal of Clinical Pharmacology 32: 533–535, 1987

    Article  PubMed  CAS  Google Scholar 

  • Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, Yaffe SJ. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 56: 1038–1044, 1975

    PubMed  CAS  Google Scholar 

  • Kercsmar CM, Stern RC, Reed MD, Myers CM, Murdell D, et al. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 289–295, 1983

    PubMed  Google Scholar 

  • Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, et al. Ceftazidime disposition in acute and stable cystic fibrosis. Clinical Pharmacology and Therapeutics 36: 355–362, 1984

    Article  PubMed  CAS  Google Scholar 

  • Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. Journal of Pediatrics 105: 117–124, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lüthy R, Blaser J, Bonetti A, Simmen H, Wise R, et al. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam and ceftazidime. Antimicrobial Agents and Chemotherapy 20: 567–575, 1981

    Article  PubMed  Google Scholar 

  • McPherson MA, Dormer RL. The molecular and biochemical basis of cystic fibrosis. Bioscience Reports 7: 167–185, 1987

    Article  PubMed  CAS  Google Scholar 

  • Norrby SR. Ceftazidime in clinical practice: a summary. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 405–408, 1983

    PubMed  Google Scholar 

  • Rowland M, Tozer TN. (Eds). Clinical pharmacokinetics: concepts and applications, 1st ed., Lea & Febiger Press, Philadelphia, 1980

    Google Scholar 

  • Rubin MI, Bruck E, Rapoport M. Maturation of renal function in childhood: clearance studies. Journal of Clinical Investigation 28: 1144–1162, 1949

    Article  CAS  Google Scholar 

  • Schachter SH, Spino M, Isles AF, Tesoro A, Prober C, et al. Pharmacokinetics of cefoperazone in patients with cystic fibrosis and healthy volunteers. Proceedings of the 13th International Congress of Chemotherapy, Vienna, August 28–September 2, 1983, pp. 45–48, 1983

  • Spino M, Chai RP, Isles AF, Balfe JW, Brown RG, et al. Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis. Journal of Pediatrics 107: 64–70, 1985

    Article  PubMed  CAS  Google Scholar 

  • Spino M, Chai RP, Isles AF, Thiessen JJ, Tesoro A, et al. Cloxacillin absorption and disposition in cystic fibrosis. Journal of Pediatrics 105: 829–835, 1984

    Article  PubMed  CAS  Google Scholar 

  • Vogelstein B, Kowarski AA, Lietman PS. The pharmacokinetics of amikacin in children. Journal of Pediatrics 91: 333–339, 1977

    Article  PubMed  CAS  Google Scholar 

  • Winberg J. The 24-hour true endogenous creatinine clearance in infants and children without renal disease. Acta Paediatrica 48: 443–452, 1959

    PubMed  CAS  Google Scholar 

  • Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M, et al. Pharmacokinetics of methicillin in patients with cystic fibrosis. Journal of Infectious Diseases 35: 828–831, 1977

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hedman, A., Adan-Abdi, Y., Alvan, G. et al. Influence of the Glomerular Filtration Rate on Renal Clearance of Ceftazidime in Cystic Fibrosis. Clin-Pharmacokinet 15, 57–65 (1988). https://doi.org/10.2165/00003088-198815010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198815010-00005

Keywords

Navigation